Literature DB >> 29205501

Predictive testing and clinical trials in Huntington's disease: An ethical analysis.

Cristina Sampaio1,2, Jamie Levey1,3, Robert Klitzman4.   

Abstract

Entities:  

Keywords:  Huntington's disease; clinical trial design; ethics; neurodegenerative diseases; predictive testing

Mesh：

Substances：

Year:  2017        PMID： 29205501      PMCID： PMC5854324          DOI： 10.1002/mds.27247

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  15 in total

1.  Predictive testing for Huntington's disease: ten years' experience in two Italian centres.

Authors:  P Mandich; G Jacopini; E Di Maria; G Sabbadini; G Abbruzzese; F Chimirri; E Bellone; A Novelletto; F Ajmar; M Frontali
Journal:  Ital J Neurol Sci       Date:  1998-04

2.  Recommendations for the predictive genetic test in Huntington's disease.

Authors:  R MacLeod; A Tibben; M Frontali; G Evers-Kiebooms; A Jones; A Martinez-Descales; R A Roos
Journal:  Clin Genet       Date:  2012-07-30       Impact factor: 4.438

3.  Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?

Authors:  Scott Yh Kim; Renee Wilson; Raymond De Vries; Kerry A Ryan; Robert G Holloway; Karl Kieburtz
Journal:  J Med Ethics       Date:  2016-03-10       Impact factor: 2.903

Review 4.  Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.

Authors:  Scott Y H Kim; Jason Karlawish; Benjamin E Berkman
Journal:  Neurology       Date:  2015-03-11       Impact factor: 9.910

Review 5.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

6.  Couples' experiences of predictive testing and living with the risk or reality of Huntington disease: a qualitative study.

Authors:  Fiona Richards
Journal:  Am J Med Genet A       Date:  2004-04-15       Impact factor: 2.802

7.  PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Authors:  Herminia D Rosas; Gheorghe Doros; Sona Gevorkian; Keith Malarick; Martin Reuter; Jean-Philippe Coutu; Tyler D Triggs; Paul J Wilkens; Wayne Matson; David H Salat; Steven M Hersch
Journal:  Neurology       Date:  2014-02-07       Impact factor: 9.910

8.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2013-05-09       Impact factor: 44.182

9.  Predictive testing for Huntington's disease: relationship with partners after testing.

Authors:  M Decruyenaere; G Evers-Kiebooms; T Cloostermans; A Boogaerts; K Demyttenaere; R Dom; J P Fryns
Journal:  Clin Genet       Date:  2004-01       Impact factor: 4.438

Review 10.  The Prevalence of Huntington's Disease.

Authors:  Michael D Rawlins; Nancy S Wexler; Alice R Wexler; Sarah J Tabrizi; Ian Douglas; Stephen J W Evans; Liam Smeeth
Journal:  Neuroepidemiology       Date:  2016-01-30       Impact factor: 3.282
View more
  1 in total

1.  Positive Attitudes and Therapeutic Misconception Around Hypothetical Clinical Trial Participation in the Huntington's Disease Community.

Authors:  Kristina Cotter; Carly E Siskind; Sharon J Sha; Andrea K Hanson-Kahn
Journal:  J Huntingtons Dis       Date:  2019
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.